# IGC PHARMA, INC. (IGC) · Edgar & Edgarette company card

> Igc Pharma (IGC) saw revenue fall 5.5% in FY2025 to $1 million, operating margin -586% against a -3.8% median for pharmaceutical preparations, equity 72.4% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1326205 · fiscal year ended 2025-03-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/IGC) · [JSON](https://www.pops4.com/boards/company/IGC.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $1M |
| Revenue growth, 1 year | -5.5% |
| Revenue growth per year | 9.1% |
| Operating margin | -585.8% (prior year -728.5%) |
| Net margin | -560.3% |
| Operating cash flow | −$5M |
| Capital spending | $112,000 |
| Free cash flow | −$5M |
| Cash | $405,000 |
| Long-term debt | $134,000 |
| Total assets | $9M |
| Total equity | $6M |
| Equity ÷ assets | 72.4% |
| Return on equity | -112.5% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -47.49 (distress zone)
- Piotroski F: 3 of 9 (middling)
- Beneish M: -3.69 (below the −1.78 line)
- Health Harbor boat: Old boat · three warning signs · operating cash flow was negative; operating loss: a margin of -585.8% in FY2025; revenue is hard to predict: its 80% range is ±76%
- Cash Compass: Fast, cash not yet · growing fast, but little cash arriving so far

## Edgarette's reading

Exposure: revenue $1.3M (FY2025), total debt $134K. Experience: revenue down 5.5% on the year, up 9.1% a year over 4 years; operating margin -585.8%, up from -728.5%. Soundness: equity 72.4% of assets, return on equity -112.5%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $560K and $4.1M next year (method v4.1: its own 5-year record of growth weighed at 57% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $488K to $4.8M. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -585.8% against a -3.8% median; growth -5.5% against 13.7%.

## Health Watch, last 12 months

No warning filings in the window.

## Recent filings

- 10-Q · filed 2026-11-06 · [filing](https://www.sec.gov/Archives/edgar/data/1326205/000118518526005237/0001185185-26-005237-index.htm)
- DEF 14A · filed 2026-10-22 · [filing](https://www.sec.gov/Archives/edgar/data/1326205/000118518526004896/0001185185-26-004896-index.htm)
- 10-Q · filed 2026-08-14 · [filing](https://www.sec.gov/Archives/edgar/data/1326205/000118518526003544/0001185185-26-003544-index.htm)
- 8-K · filed 2026-07-14 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1326205/000118518526002922/0001185185-26-002922-index.htm)
- 8-K · filed 2026-07-06 · 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1326205/000118518526002808/0001185185-26-002808-index.htm)
- 8-K · filed 2026-06-08 · 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1326205/000118518526002410/0001185185-26-002410-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001326205.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1326205

## Cite

POPS4, Edgar & Edgarette: IGC PHARMA, INC. (IGC) company card, from the company's own SEC filings, accessed 2026-11-19, https://www.pops4.com/boards/company/IGC. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.

